BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

312 related articles for article (PubMed ID: 15088311)

  • 1. Serum level of KL-6 as a marker of interstitial lung disease in patients with juvenile systemic sclerosis.
    Veselý R; Vargová V; Ravelli A; Massa M; Oleksák E; D'Alterio R; Martini A; De Benedetti F
    J Rheumatol; 2004 Apr; 31(4):795-800. PubMed ID: 15088311
    [TBL] [Abstract][Full Text] [Related]  

  • 2. KL-6 is a potential marker for interstitial lung disease associated with juvenile dermatomyositis.
    Kobayashi I; Ono S; Kawamura N; Okano M; Miyazawa K; Shibuya H; Kobayashi K
    J Pediatr; 2001 Feb; 138(2):274-6. PubMed ID: 11174630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum levels of KL-6 as a useful marker for evaluating pulmonary fibrosis in patients with systemic sclerosis.
    Yamane K; Ihn H; Kubo M; Yazawa N; Kikuchi K; Soma Y; Tamaki K
    J Rheumatol; 2000 Apr; 27(4):930-4. PubMed ID: 10782818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative study of serum surfactant protein-D and KL-6 concentrations in patients with systemic sclerosis as markers for monitoring the activity of pulmonary fibrosis.
    Yanaba K; Hasegawa M; Takehara K; Sato S
    J Rheumatol; 2004 Jun; 31(6):1112-20. PubMed ID: 15170923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical significance of surfactant protein D as a serum marker for evaluating pulmonary fibrosis in patients with systemic sclerosis.
    Asano Y; Ihn H; Yamane K; Yazawa N; Kubo M; Fujimoto M; Tamaki K
    Arthritis Rheum; 2001 Jun; 44(6):1363-9. PubMed ID: 11407696
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical significance of serum KL-6 and SP-D for the diagnosis and treatment of interstitial lung disease in patients with diffuse connective tissue disorders].
    Ogawa N; Shimoyama K; Kawabata H; Masaki Y; Wano Y; Sugai S
    Ryumachi; 2003 Feb; 43(1):19-28. PubMed ID: 12692986
    [TBL] [Abstract][Full Text] [Related]  

  • 7. KL-6 as a novel serum marker for interstitial pneumonia associated with collagen diseases.
    Nakajima H; Harigai M; Hara M; Hakoda M; Tokuda H; Sakai F; Kamatani N; Kashiwazaki S
    J Rheumatol; 2000 May; 27(5):1164-70. PubMed ID: 10813282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Elevated serum Krebs von den Lungen-6 in systemic sclerosis: a marker of lung fibrosis and severity of the disease.
    Benyamine A; Heim X; Resseguier N; Bertin D; Gomez C; Ebbo M; Harlé JR; Kaplanski G; Rossi P; Bardin N; Granel B
    Rheumatol Int; 2018 May; 38(5):813-819. PubMed ID: 29455320
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Assessment of serum markers KL-6 and SP-D for interstitial pneumonia associated with connective tissue diseases].
    Suematsu E; Miyamura T; Shimada H; Nakao R; Yamamoto M
    Ryumachi; 2003 Feb; 43(1):11-8. PubMed ID: 12692985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum KL-6 and surfactant proteins A and D in pediatric interstitial lung disease.
    Al-Salmi QA; Walter JN; Colasurdo GN; Sockrider MM; Smith EO; Takahashi H; Fan LL
    Chest; 2005 Jan; 127(1):403-7. PubMed ID: 15654008
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Use of the the ED046 kit to analyze serum KL-6 in patients with pneumonitis].
    Kitamura S; Hiwada K; Kobayashi J; Kohno N; Kawai T; Satou A; Kasukawa R; Kawakami Y; Andou M; Nakada G; Inoue H; Itou K; Matsushima T; Ogura T; Arakawa M; Yamakido M
    Nihon Kyobu Shikkan Gakkai Zasshi; 1996 Jun; 34(6):639-45. PubMed ID: 8741528
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Increased levels of KL-6 and subsequent mortality in patients with interstitial lung diseases.
    Satoh H; Kurishima K; Ishikawa H; Ohtsuka M
    J Intern Med; 2006 Nov; 260(5):429-34. PubMed ID: 17040248
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum marker KL-6/MUC1 for the diagnosis and management of interstitial pneumonitis.
    Kohno N
    J Med Invest; 1999 Aug; 46(3-4):151-8. PubMed ID: 10687309
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Clinical usefulness of KL-6 as a serum marker of idiopathic interstitial pneumonia].
    Kohno N
    Nihon Kyobu Shikkan Gakkai Zasshi; 1996 Dec; 34 Suppl():186-9. PubMed ID: 9216213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The clinical study on KL-6 and SP-D in sera of patients with various pulmonary diseases].
    Sugimoto H; Okada E; Hashimoto N; Suzuki S; Yoshida H; Totani Y; Ameshima S; Ishizaki T; Miyamori I
    Rinsho Byori; 2000 Jun; 48(6):554-60. PubMed ID: 10897675
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Performance of Candidate Serum Biomarkers for Systemic Sclerosis-Associated Interstitial Lung Disease.
    Elhai M; Hoffmann-Vold AM; Avouac J; Pezet S; Cauvet A; Leblond A; Fretheim H; Garen T; Kuwana M; Molberg Ø; Allanore Y
    Arthritis Rheumatol; 2019 Jun; 71(6):972-982. PubMed ID: 30624031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serum pulmonary and activation-regulated chemokine/CCL18 levels in patients with systemic sclerosis: a sensitive indicator of active pulmonary fibrosis.
    Kodera M; Hasegawa M; Komura K; Yanaba K; Takehara K; Sato S
    Arthritis Rheum; 2005 Sep; 52(9):2889-96. PubMed ID: 16142750
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correlation of the degree of dyspnea with health-related quality of life, functional abilities, and diffusing capacity for carbon monoxide in patients with systemic sclerosis and active alveolitis: results from the Scleroderma Lung Study.
    Khanna D; Clements PJ; Furst DE; Chon Y; Elashoff R; Roth MD; Sterz MG; Chung J; FitzGerald JD; Seibold JR; Varga J; Theodore A; Wigley FM; Silver RM; Steen VD; Mayes MD; Connolly MK; Fessler BJ; Rothfield NF; Mubarak K; Molitor J; Tashkin DP;
    Arthritis Rheum; 2005 Feb; 52(2):592-600. PubMed ID: 15692967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biomarkers to identify ILD and predict lung function decline in scleroderma lung disease or idiopathic pulmonary fibrosis.
    Kennedy B; Branagan P; Moloney F; Haroon M; O'Connell OJ; O'Connor TM; O'Regan K; Harney S; Henry MT
    Sarcoidosis Vasc Diffuse Lung Dis; 2015 Sep; 32(3):228-36. PubMed ID: 26422568
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence and characteristics of moderate to severe pulmonary hypertension in systemic sclerosis with and without interstitial lung disease.
    Launay D; Mouthon L; Hachulla E; Pagnoux C; de Groote P; Remy-Jardin M; Matran R; Lambert M; Queyrel V; Morell-Dubois S; Guillevin L; Hatron PY
    J Rheumatol; 2007 May; 34(5):1005-11. PubMed ID: 17444586
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.